Oncology

What started out as a journey to better understand regulatory T cells has now led to an intriguing approach with an investigational cell therapy designed to prevent the risk of graft-versus-host disease and to improve relapse-free survival rates in patients undergoing hematopoietic stem cell transplantation.

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

An off-the-shelf CAR T-cell therapy that targets B-cell maturation antigen, ALLO-715, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel was found to yield clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.

December 6, 2020 - Odronextamab, is a novel CD20xCD3 bispecific antibody, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

Results were released for a leading chimeric antigen receptor (CAR) T-cell therapy candidate in multiple myeloma, along with long-term findings for an early treatment that may soon face competition.

City of Hope's Dr. Tanya Siddiqi offers an update on a new chimeric antigen receptor (CAR) T-cell therapy awaiting approval from the FDA.

The emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

Immune-associated neurotoxicity in patients following chimeric antigen receptor (CAR) T-cell therapy may be due to monocyte-like cells in infusion products, explained Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.

The vice president for Clinical Services at OneOncology describes challenges and opportunities for chimeric antigen receptor (CAR) T-cell therapy in the community practice setting.

Faiz Anwer, MD, discusses the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.

Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.

Abhinav Deol, MD, highlights the progress that has been made with CAR T-cell therapy in leukemia and lymphoma, challenges faced with regard to accessibility and toxicity, and next steps for this modality.

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment.

Chimeric antigen receptor (CAR) T-cell therapy does not always lead to a durable response, and we are trying to figure out why, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.

The process of approving a new therapy for relapsing and/or remitting mantle cell lymphoma therapy got off to a faster start in China, but United States regulators caught up and approved the drug first.

Andre Goy, MD, of John Theurer Cancer Center, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.

David H. Vesole, MD, PhD, discusses the evolution of multiple myeloma treatment, and explained how other BCMA-therapies are poised to impact clinical practice.

Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.

A new chimeric antigen receptor (CAR) T cell therapy may help curb the problem of frequent relapse in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

Combining chimeric antigen receptor (CAR) T-cell therapy and an oncolytic virus were more potent against solid tumors than CAR T-cell therapy alone in mouse models of cancer.

A significant number of patients who undergo chimeric antigen receptor (CAR) T-cell therapy will experience severe neurotoxicity. A new study could help doctors better predict which patients are at risk.

Blinatumomab monotherapy as consolidation therapy prior to allogeneic hematopoietic stem cell transplant resulted a significant improvement in event-free survival and a lower risk of recurrence in children with high-risk B-cell precursor–acute lymphoblastic leukemia.